Navigation Links
GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

LONDON and CRANBURY, N.J., Oct. 29 /PRNewswire/ -- GlaxoSmithKline PLC (GSK) and Amicus Therapeutics (Nasdaq: FOLD) today announced a definitive agreement to develop and commercialize Amigal (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease, a rare inherited disorder.  Under the terms of the agreement, GSK will receive an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl.  Additionally, as part of the agreement GSK and Amicus also intend to advance clinical studies exploring the co-administration of migalastat HCl with enzyme replacement therapy (ERT) for the treatment of Fabry disease. 

Under the terms of the Agreement, Amicus will receive an upfront, license payment of $30M from GSK and is eligible to receive further payments of approximately $170M upon the successful achievement of development and commercialization milestones, as well as tiered double-digit royalties on global sales of migalastat HCl. GSK and Amicus will jointly fund development costs in accordance with an agreed upon development plan.   Additionally, as part of the collaboration, GSK is purchasing 6.9 million shares of Amicus common stock at a price of $4.56 per share.  The total value of this equity investment to Amicus is $31 million and represents a 19.9% ownership position for GSK in the Company.  The total cash up-front to Amicus from GSK for the upfront license payment and equity investment is approximately $60 million.

"This strategic collaboration is another significant milestone in delivering our vision for GSK Rare Diseases. Amicus' scientific and clinical expertise in human genetic diseases is among the best in the industry, and we are pleased to be collaborators and investors in this exceptional company," said Marc Dunoyer, Global Head of GSK Rare Diseases and a member of the GSK Corp
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Germany Gynecological ... GlobalData,s new report, "Germany Gynecological Devices Market ... the Germany Gynecological Devices market. The report provides ... units) and average prices (in US dollars) within ... Devices (Micro-inserts) and Mechanical Sterilization Devices (Tubal Clips ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... of PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... PDL BioPharma and certain of its officers and/or directors ... Exchange Act of 1934.  On September ...
(Date:9/17/2014)... 17, 2014 Bronstein, Gewirtz & Grossman, LLC ... the securities of PDL BioPharma, Inc. ("PDL BioPharma" or ... investors are advised to contact Peretz Bronstein ... at info@bgandg.com or 212-697-6484. The ... its executives violated federal securities laws. On ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
(Date:9/18/2014)... (PRWEB) September 18, 2014 First ... freestanding emergency rooms in the United States, named Douglas ... new Missouri City-Lakes facility. , “We are pleased ... facility medical director of our new Missouri City-Lakes facility,” ... First Choice Emergency Room. , Dr. Harrison received ...
(Date:9/18/2014)... 18, 2014 9Lover.com, an internationally well-known ... recently launched a big promotion for its maternity wedding ... can buy discounted maternity wedding dresses on ... appreciation to all global consumers. The company’s development manager ... lot of ladies delighted. The current special offer will ...
(Date:9/17/2014)... 2014 A ball gown is the ... traditionally a full-skirted gown reaching the floor, made of ... well-known special occasion gown manufacturer and retailer, has delightedly ... gorgeous ball gowns are offered at discounted rates. , ... necklines. Such gowns are typically worn with a stole ...
(Date:9/17/2014)... The National Resident Matching Program has published ... analysis of the relationship between unique applicant characteristics and ... new edition is based on the 2014 Main Residency ... medical school senior students and all other applicants. , ... this new edition of Charting Outcomes in the Match,” ...
(Date:9/17/2014)... 2014 In its latest blog post, ... alcohol treatment program that gets clients off to a ... recovery they can believe in, is exploring the dangerous ... Americans who are afflicted with depression are also addicted ... CEO Per Wickstrom . “Unfortunately, these two very ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:Fecbek.com: Ladies Can Be Elegant Enough to Draw Everyone’s Attention by Wearing Trendy Ball Gowns 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 2Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 3
... seek answers to questions of motivation and self-actualization. "Make ... Honaman employs lessons learned in his career working with ... to help others direct their energies and develop their ... "Make It Happen" that personal branding is the process ...
... 20 Hooper Holmes, Inc. (Amex: HH ... Health and Wellness Division, Christopher J. Behling, will be ... Colloquium on Tuesday, March 3, 2009 at 9:00 a.m. ... Regency at Penn,s Landing in Philadelphia, Pennsylvania. Mr. Behling,s ...
... Faced with news of increasing layoffs, straining economic times, ... hiring is based on looks, millions of American women ... them a competitive edge in the workplace. In a ... of 18 and 64 compiled by the ASPS, many ...
... 20 The Niwano Peace Foundation announced Friday it will ... Baguma Byamugisha, an Anglican priest of Uganda, in recognition of ... people living with HIV/AIDS.An award presentation ceremony will take place ... award certificate, Rev. Byamugisha will receive a medal and 20 ...
... York, NY, February 20, 2009 Although widespread Prostate-Specific-Antigen ... there a point of diminishing returns? In a study ... Journal of Urology , researchers found that in a ... years old or older and had a PSA below ...
... in chronic obstructive lung disease (COPD) themselves increase ... days of full, asymptomatic recoverybad news for patients ... progression of the disease. , "This concept ... for the analysis of clinical trial data and ...
Cached Medicine News:Health News:Business Strategist Applies Corporate Experience to Self-Help: 'Make It Happen' 2Health News:Hooper Holmes to Present at the Ninth Population Health and Disease Management Colloquium 2Health News:Hooper Holmes to Present at the Ninth Population Health and Disease Management Colloquium 3Health News:In Today's Economy, Women In The Workforce Link Cosmetic Chicago Plastic Surgery To Success 2Health News:In Today's Economy, Women In The Workforce Link Cosmetic Chicago Plastic Surgery To Success 3Health News:Rev. Byamugisha of Uganda to Receive Niwano Peace Prize 2Health News:When should prostate-specific antigen testing be stopped? 2Health News:Exacerbations in COPD: One thing leads to another 2Health News:Exacerbations in COPD: One thing leads to another 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: